Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
12.42 USD -0.28 ( 2.20%)
Last update at 2026-11-20T21:00:00Z
VOLUME
705602
Market Cap
855.68M
P/E
12.29

Momentum Score

…

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.40
Low
12.67
High
52 Week Price Range
12.72
Low
16.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

InMode Ltd is an Israeli medical technology company that develops and commercializes minimally invasive and non‑invasive aesthetic treatment platforms primarily using radiofrequency and other energy‑based technologies. Long‑term growth may be supported by aging demographics, rising demand for non‑surgical cosmetic procedures, international expansion and ongoing product innovation that can generate recurring device and consumable sales. Investors may find the company attractive because it appears positioned with differentiated technology and a business model tied to physician adoption and procedure volumes.

Investors should monitor material risks including sensitivity to discretionary healthcare spending and procedure volumes, competitive pressure from larger med‑tech firms, regulatory and clinical approval requirements, and execution risk in sustaining product innovation and global commercial expansion.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.70
Dividend Yield
-
Revenue TTM
374.62M
Revenue Per Share
6.02
Gross Profit TTM
286.68M
Debt / Equity
0.02
ROE
12.33%
Net Debt
-289.31M
ROCE
15.86%
Diluted EPS TTM
1.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 110.33M 143.47M 217.27M 201.47M 168.00M
Minority interest - - 0.00M 0.00M -0.10M
Net income 93.83M 181.28M 197.92M 161.52M 164.97M
Selling general administrative 11.69M 10.03M 9.23M 9.93M 8.41M
Selling and marketing expenses 180.58M 181.37M 193.04M 160.58M 119.35M
Gross profit 290.97M 317.07M 411.34M 380.79M 303.97M
Reconciled depreciation 0.69M 0.73M 0.62M 0.68M 0.52M
Ebit 110.33M 143.47M 217.27M 197.85M 167.48M
Ebitda 111.03M 144.20M 217.89M 198.53M 167.99M
Depreciation and amortization 0.69M 0.73M 0.62M 0.68M 0.52M
Operating income 85.39M 112.53M 195.66M 197.85M 167.48M
Other operating expenses 285.11M 282.29M 296.39M 256.42M 190.09M
Interest expense - - - 3.61M 0.42M
Tax provision 16.50M -37.81M 19.35M 39.95M 2.93M
Interest income 24.94M 30.94M 21.61M 3.61M 0.53M
Net interest income 24.94M 30.94M 21.61M 3.61M 0.53M
Income tax expense 16.50M -37.81M 19.35M 39.95M 2.93M
Total revenue 370.50M 394.82M 492.05M 454.27M 357.56M
Total operating expenses 205.58M 204.53M 215.68M 182.93M 136.50M
Cost of revenue 79.53M 77.75M 80.71M 73.48M 53.59M
Total other income expense net 24.94M 30.94M 21.61M 3.61M 0.53M
Net income from continuing ops 93.83M 181.28M 197.92M 161.52M 165.07M
Net income applicable to common shares - - - 161.52M 164.97M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 766.43M 785.67M 863.29M 644.41M 478.54M
Other current assets 4.63M 17.38M 15.00M 13.83M 8.40M
Total liab 83.23M 81.85M 75.91M 89.79M 62.74M
Total stockholder equity 683.20M 703.81M 787.37M 554.62M 415.80M
Other current liab 49.61M 35.87M 36.84M 50.53M 28.06M
Common stock 0.25M 0.25M 0.24M 0.24M 0.24M
Capital stock 0.25M 0.25M 0.24M 0.24M 0.24M
Retained earnings 968.53M 874.70M 693.43M 495.51M 333.99M
Other liab - - - 4.26M 7.58M
Other assets - - - 7.07M 2.10M
Cash 302.54M 155.33M 144.41M 97.54M 68.14M
Total current liabilities 70.74M 69.85M 64.14M 82.02M 51.85M
Current deferred revenue - 16.75M 10.92M 13.80M 13.80M
Net debt -289.31M -147.51M -135.39M -92.58M -64.83M
Short term debt 3.22M 2.51M 2.40M 1.45M 1.21M
Short long term debt total 13.23M 7.82M 9.02M 4.96M 3.31M
Other stockholder equity -285.65M -170.80M 95.38M 66.36M 82.89M
Property plant equipment - - - 7.37M 5.72M
Total current assets 698.62M 714.45M 845.33M 629.37M 470.11M
Long term investments 0.70M 0.70M 0.70M 0.60M 0.60M
Net tangible assets - - - 554.62M 415.80M
Short term investments 252.79M 441.14M 597.19M 449.84M 347.78M
Net receivables 49.28M 41.05M 43.63M 42.09M 33.17M
Inventory 89.37M 59.55M 45.09M 39.90M 21.03M
Accounts payable 17.91M 13.78M 13.97M 16.24M 8.78M
Accumulated other comprehensive income 0.07M -0.34M -1.68M -7.49M -1.32M
Non currrent assets other 3.00M 3.18M 3.67M 3.97M 0.77M
Non current assets total 67.81M 71.22M 17.96M 15.04M 8.43M
Capital lease obligations 8.23M 7.82M 9.02M 4.96M 4.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 187.00M 162.21M -122.65M -109.47M -159.17M
Change to liabilities - - - 8.66M 5.04M
Total cashflows from investing activities 186.03M 162.21M -136.06M -109.47M -160.11M
Total cash from financing activities -126.06M -282.77M 5.50M -41.09M -15.02M
Change to operating activities - - - 16.15M 7.74M
Net income 93.83M 181.28M 197.92M 161.52M 165.07M
Change in cash 147.21M 10.92M 46.87M 29.40M -0.80M
Begin period cash flow 155.33M 144.41M 97.54M 68.14M 68.94M
End period cash flow 302.54M 155.33M 144.41M 97.54M 68.14M
Total cash from operating activities 85.26M 132.66M 176.83M 181.58M 174.88M
Issuance of capital stock - - - - 0.00M
Depreciation 0.69M 0.73M 0.62M 0.68M 0.52M
Other cashflows from investing activities - - -135.36M - -
Change to inventory -14.50M -14.45M -5.20M -18.87M -6.04M
Change to account receivables -11.13M 0.25M -18.31M -10.41M -10.54M
Sale purchase of stock -127.44M -285.38M 0.00M -42.64M -35.37M
Other cashflows from financing activities - 2.61M 5.50M 1.55M 20.34M
Change to netincome - - - 23.85M 13.21M
Capital expenditures 0.97M 0.67M 0.70M 1.57M 0.94M
Change in working capital -24.30M -7.07M -41.44M -4.47M -3.81M
Stock based compensation 11.13M 16.57M 23.60M 24.45M 11.96M
Other non cash items 0.97M -3.66M -3.69M -0.69M 1.91M
Free cash flow 84.28M 132.00M 176.12M 180.00M 173.95M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INMD
InMode Ltd
-0.28
2.20%
12.42 12.29 10.48 2.28 1.36 0.96 5.15
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

InMode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Tavor Building, Yokne'am, Israel, 2069206

972 4 909 6313

660

Name Title Year Born
Mr. Yair Malca Chief Financial Officer 1978
Mr. Alon Yaari VP of Operations NA
Ms. Nava Tal-Launer Chief Information Officer NA
Mr. Shakil Lakhani Pres of North America 1983
Dr. Spero Theodorou M.D. Chief Medical Officer 1972
Mr. Moshe Mizrahy Chairman & CEO 1953
Dr. Michael Kreindel CTO & Director 1968
Mr. Shakil Lakhani President of North America 1983
Mr. Alon Yaari Vice President of Operations NA
Dr. Michael Kreindel Co-Founder, CTO & Director 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…